These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 11840415)

  • 1. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Thigpen T
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
    Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
    Bunn PA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental chemotherapy and management of recurrent ovarian cancer.
    Bookman MA
    J Clin Oncol; 2003 May; 21(10 Suppl):149s-167s. PubMed ID: 17633784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
    Bookman MA
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):20-31. PubMed ID: 11840417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
    Thigpen T
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
    Pujol JL; Barlesi F; Daurès JP
    Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy with topotecan for non-small cell lung cancer.
    Dowlati A; Levitan N
    Lung Cancer; 2003 Aug; 41 Suppl 4():S23-6. PubMed ID: 14565511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Gynecologic Oncology Group experience in ovarian cancer.
    McGuire WP; Brady MF; Ozols RF
    Ann Oncol; 1999; 10 Suppl 1():29-34. PubMed ID: 10219450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
    Copeland LJ; Bookman M; Trimble E;
    Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S1-7. PubMed ID: 12927999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.